<DOC>
	<DOCNO>NCT02598570</DOCNO>
	<brief_summary>This study seek evaluate safety pharmacokinetics duvelisib Japanese participant relapse refractory lymphoma .</brief_summary>
	<brief_title>Study Evaluating Duvelisib Japanese Subjects With Relapsed Refractory Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Diagnosis lymphoma ( exclude lymphoblastic lymphoma ) Progressed , refractory , intolerant , ineligible establish therapy , disease establish therapy Eastern Cooperative Oncology Group ( ECOG ) performance status low equal 2 Life expectancy least 3 month Any prior treatment PI3K inhibitor Bruton 's tyrosine kinase ( BTK ) inhibitor Ongoing treatment chronic immunesuppressants Overt CNS lymphoma Inadequate hepatic , bone marrow , renal function History stroke , unstable angina , myocardial infarction , ventricular arrhythmia require medication mechanical control within last 6 month Venous thromboembolic event require anticoagulation Presence active systemic infection within 72 hour treatment Human immunodeficiency virus ( HIV ) infection Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Relapsed Lymphoma</keyword>
	<keyword>Phosphoinositide 3-kinase ( PI3K ) Inhibitor</keyword>
	<keyword>Duvelisib</keyword>
	<keyword>Japanese</keyword>
	<keyword>Refractory Lymphoma</keyword>
</DOC>